98%
921
2 minutes
20
Pt(ii) complexes cis-N,N-[PtCl(C^N)(N'^C'H)], where C^N represents a monocyclometalated 2,6-diaryl- or 2-arylpyridine ligand and N'^C'H is an N-coordinated 2-arylpyridine, are selectively obtained from bridge-cleavage reactions of dimers [Pt(μ-Cl)(C^N)] with excess N'^C'H at room temperature; isolation and characterization of derivatives of this kind is reported for the first time. Oxidation with PhICl affords Pt(iv) complexes [PtCl(C^N)(C'^N')], bearing two cyclometalated ligands in an unsymmetrical arrangement. The abstraction of the two chlorides using AgOTf at 120 °C in the presence of an additional 2-arylpyridine ligand leads to mer isomers of tris-cyclometalated Pt(iv) complexes if C^N derives from a 2-arylpyridine, whereas it results in a reductive C-C coupling if C^N is a monocyclometalated 2,6-diarylpyridine. Complexes [PtCl(C^N)(C'^N')] show phosphorescence in frozen PrCN glasses arising from essentially LC excited states localized on the cyclometalated ligand with the lowest π-π* transition energy. The combined photophysical data and computational results substantiate a variable degree of MLCT admixture into the emitting state depending on the atom trans to the metalated carbon of the chromophoric ligand (Cl or N), which has an appreciable effect on the characteristics of the observed luminescence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c9dt02431j | DOI Listing |
J Inorg Biochem
December 2025
Department of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom. Electronic address:
Photoactive Pt(IV) complexes conjugated to amino acid methyl esters trans,trans,trans-[Pt(py)(N)(OH)(succinate-amino acid methyl ester)] (amino acid = L-leucine (1), glycine (2), L-tyrosine (3) and L-tryptophan (4)) have been synthesised and characterised. Complexes 1-4 showed high dark stability, but were activated upon irradiation with blue light to generate azidyl and hydroxyl radicals and Pt(II) species. Interestingly, conjugated tryptophan in 4 quenched the formation of azidyl and hydroxyl radicals and Pt-guanosine 5'-monphosphate adducts, while the amino acids in complexes 1-3 showed no significant effects on the formation of their photoproducts.
View Article and Find Full Text PDFDalton Trans
September 2025
Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy.
Platinum(IV) prodrugs offer a promising strategy to overcome the limitations of cisplatin and oxaliplatin, including systemic toxicity and acquired resistance. In this study, two novel α-tocopherol succinate-functionalized Pt(IV) complexes, [Pt(oxalato)(DACH)(OAc)(α-TOS)] (4) and [PtCl(NH)(OAc)(α-TOS)] (5), were synthesized and characterized to enhance the efficacy and selectivity of platinum-based chemotherapy. Functionalization with α-TOS (3) was designed to increase lipophilicity and enable selective intracellular reduction.
View Article and Find Full Text PDFAcc Chem Res
August 2025
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Guangdong 518107, P. R. China.
ConspectusPhotodynamic therapy (PDT), which uses a photosensitizer (PS) to produce reactive oxygen species (ROS), has attracted great attention for cancer therapy. However, the hypoxic microenvironment within solid tumors strongly inhibits the PDT efficiency. Therefore, developing novel phototherapeutic strategies is urgently needed.
View Article and Find Full Text PDFMolecules
July 2025
Department of Analytical Chemistry, Faculty of Chemistry, Institute of Chemical Sciences, Maria Curie-Sklodowska University, M. C. Sklodowska Sq. 3, 20-031 Lublin, Poland.
Spent automobile catalysts can be an important source of platinum for industry applications. Low-cost and simple technologies for platinum recovery from this source are sought, especially involving the application of green adsorbents. Honeycomb biowaste can be an excellent candidate for this purpose; n-hexane-treated honeycomb biowaste is therefore obtained for the first time.
View Article and Find Full Text PDFJ Inorg Biochem
November 2025
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, PR China. Electronic address:
Classical cisplatin-based chemotherapeutic drugs are widely used in clinical practice. In recent years, novel platinum-based antitumor drugs have focused on replacing classical cisplatin-like Pt(II) complexes with relatively inert Pt(IV) prodrugs to overcome drug resistance and reduce toxic side effects. Based on the excellent physiological and pharmacological activities of cannabidiol (CBD), this study designed and synthesized novel Pt(IV) prodrugs W1-W6, which are axial conjugates of cisplatin with CBD and specific active small molecules.
View Article and Find Full Text PDF